Only in Titles

           Search results for: Beta Amyloid (1 40) ELISA Kit, Human   

paperclip

#23302661   // Save this To Up

Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.

The aim of this study was to validate new assays for measurement of amyloid-β (Aβ) peptides in cerebrospinal fluid (CSF) and plasma specimens in clinical studies of solanezumab according to current regulatory recommendations. Four assays based on the INNOTEST® β-AMYLOID(1-42) and prototype INNOTEST β-AMYLOID(1-40) kits were developed and validated. To render these assays 'solanezumab-tolerant', excess drug was added to calibrators, quality control, and test samples via a 2-fold dilution with kit diluent. Validation parameters were evaluated by repeated testing of human CSF and EDTA-plasma pools containing solanezumab. Calibration curve correlation coefficients for the four assays were ≥0.9985. Intra- and inter-assay coefficients of variation for Aβ1-40 and Aβ1-42 were ≤13 and ≤15%, respectively for both matrices. Dilutional linearity, within and between assays, was demonstrated for both analytes in CSF and plasma at clinically relevant dilution factors. This dilution regimen was successfully applied during Phase 3 clinical sample analysis. Aβ1-40 and Aβ1-42 were stable in CSF and plasma containing solanezumab at 2-8°C and room temperature for up to 8 h and during 5 additional freeze-thaw cycles from ≤-20 and ≤-70°C. Results of parallel tests on stored clinical samples using INNOTEST methods and proprietary ELISA methods were closely correlated (r2 > 0.9), although bias in reported concentrations was observed between assays. In conclusion, the modified INNOTEST assays provided (relatively) accurate and precise quantification of Aβ1-40 and Aβ1-42 in CSF and plasma containing solanezumab according to established consensus validation criteria. The clinical experience with these assays post validation has shown them to be robust and reliable.

2812 related Products with: Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.

Beta Amyloid (1 40) ELISA Beta Amyloid (42) ELISA K Beta Amyloid (1 40) ELISA Beta Amyloid (40) ELISA K Syringe pump can be contr Breast disease spectrum t Ovary disease spectrum (o Monkey serum amyloid A1 ( Multiple lung carcinoma ( Caspase 4 Inhibitor Drug HCV antibody test strip, CETP Inhibitor Drug Scree

Related Pathways

  •  
  • No related Items
paperclip

#22216291   // Save this To Up

Association between IgM anti-herpes simplex virus and plasma amyloid-beta levels.

Herpes simplex virus (HSV) reactivation has been identified as a possible risk factor for Alzheimer's disease (AD) and plasma amyloid-beta (Aβ) levels might be considered as possible biomarkers of the risk of AD. The aim of our study was to investigate the association between anti-HSV antibodies and plasma Aβ levels.

1706 related Products with: Association between IgM anti-herpes simplex virus and plasma amyloid-beta levels.

Goat Anti-Herpes Simplex Goat Anti-Herpes Simplex Mouse Anti-Herpes Simplex Goat Anti-Herpes Simplex Goat Anti-Herpes Simplex Rabbit Anti-beta-Amyloid( Mouse Anti-beta-Amyloid(1 Mouse Anti-beta-Amyloid(1 Rabbit Anti-beta-Amyloid( Mouse Anti-beta-Amyloid(1 Anti-BACE-1 (Memapsin-2, Mouse Anti-beta-Amyloid(1

Related Pathways

  •  
  • No related Items
paperclip

#21047883   // Save this To Up

CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.

The clinical distinction between Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) is sometimes difficult, particularly in mild cases. Although CSF markers such as amyloid β42 (Aβ42) and P-tau can distinguish between AD and normal controls, their ability to distinguish between AD and DLB is not adequate.

2238 related Products with: CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.

MarkerGeneTM Fluorescent MarkerGene™ LysoLive™ MarkerGene™ Total Prote Cultrex In Vitro Angiogen MarkerGeneTM Live Dead As MarkerGeneTM Gaussia Luci QuantiChrom™ Formaldehy MarkerGene™ Cellular Se Marker Gene™ Non-Radioa MarkerGeneTM Fluorescent MarkerGeneTMFluorescent A MarkerGene™ Multiple Dr

Related Pathways

  •  
  • No related Items